

PEDIATRIC CANCER DATA COMMONS

Happy new year from the [Pediatric Cancer Data Commons](#)! If you're new to the PCDC, welcome to our quarterly newsletter. Its purpose is to highlight opportunities to get more involved, make it easier to learn from each other as we work toward common goals, and facilitate cross-disease research collaborations. Past newsletters are [archived on our website](#). Please don't hesitate to [reach out with your suggestions and requests](#).



Hello from our first hybrid remote and in-person team meeting!

Keep in touch with us!



You're Invited

Please join us Tuesday, January 25 at 11am CT for [The Common Good](#), a quarterly series of thought leadership talks hosted by the PCDC.



Putting Children First: New Models for Pediatric Oncology Drug Development

Join Sam Blackman, MD, PhD, co-founder and Chief Medical Officer of Day One Biopharmaceuticals, for a discussion of how pediatric oncology drug development can change for the better. Dr. Blackman, who has led the early clinical development of more than 10 novel cancer therapeutics, will describe the challenges that have limited the pace of development of new therapeutics for pediatric cancer, new business models that may be capable of changing this dynamic, and how the pediatric oncology ecosystem can work together to enable success.

[Register](#)



2020-21 Annual Report

In case you missed it, we are delighted to share the newest PCDC Annual Report, which illustrates our progress over the period of July 2020-June 2021.

[Browse the report online or download a PDF copy here.](#)

Announcements

New publication on PCDC methods

In a new publication, the PCDC team and collaborators present our experience constructing the Pediatric Cancer Data Commons to highlight the significance of developing a rich and robust data ecosystem for pediatric oncology and to provide essential information to those creating resources in other disease areas. We identify six critical features of successful data commons design and implementation that can be extended to any clinical area. Read the paper here: [Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research](#).

"The future of clinical trials is here. Are we?"

In October, we kicked off [The Common Good](#) speaker series with Greg Simon, former President of the Biden Cancer Initiative, who spoke about what we can learn from the last two years to make clinical trials more accessible, equitable, and patient-focused. If you missed the talk, [you can watch it here](#).

Developing a commons for the sociome

PCDC Director Sam Volchenboum gave a Grand Rounds talk describing one of our newest initiatives: working with many partners at UChicago and beyond to develop a data commons for the sociome. [Watch the talk here](#).

Welcoming the Scientific Advisory Committee

The latest step in the PCDC's growth is the establishment of advisory groups. While each consortium maintains autonomy in its own operations and scientific direction, our new Scientific Advisory Committee (SAC) will provide strategic and operational guidance for the PCDC. Composed of international consortium representatives and domain experts, the SAC launched in November 2021. [Meet the members here](#).

Meeting highlight: GEARBOX poster

The PCDC team and collaborators presented a poster at the 53rd Congress of the International Society of Paediatric Oncology (SIOP 2021) which took place virtually October 21-24, 2021. View the poster here: [Genomic Eligibility Algorithm At Relapse For Better Outcomes \(GEARBOX\): A decision support tool for matching children with relapsed acute myeloid leukemia to clinical trials](#).

PCDC team update


This quarter we were happy to officially welcome [Ellen Cohen](#) to the PCDC team as our Senior Director of Academic Operations.

We're hiring!

The PCDC is growing! We invite you to share our job posting for a [Full Stack Developer](#) with your network.

Disease Group Milestones

The PCDC Consortium is currently composed of ten individual disease groups, each in its own stage of development. Stay informed about the accomplishments of each disease group and see what your colleagues across the globe are working on!



Data commons progress as of January 2022. Learn more about these milestones [here](#).

ALL

- Data contributors are in the process of finalizing clinical trials to include in the ALL commons.
- Work to engage international partners continues.

AML (INTERACT)

- A data contributor agreement with St. Jude is in the final stages.
- Data contributors continue to harmonize data for the INTERACT commons.

Bone Tumors (HIBISCUS)

- The HIBISCUS Executive Committee is finalizing six work groups, which will each focus on a specific area of work and facilitate the creation of research ideas for the commons.
- Work continues with institutional leaders and the UChicago legal team to execute data contributor agreements.

CNS Tumors (INSPIRE)

- INSPIRE made significant progress this quarter on the CNS data dictionary through dedicated bi-weekly meetings.
- Work to create data governance and policies and procedures for data release has begun.

Germ Cell Tumors (MaGIC)

- MaGIC has only one remaining data contributor agreement to be signed.
- Newly created Pathology and Survivorship Committees are working with the PCDC to incorporate relevant retrospective and prospective data into the GCT Data Commons.

Hodgkin Lymphoma (NODAL)

- NODAL continues to hold planning meetings, with the focus on harmonizing COG and St. Jude data and creating the charges for clinical work groups.

Neuroblastoma (INRG)

- A new INRG paper was published in *JCO Clinical Cancer Informatics*: [Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group](#).

Predisposition (C3P)

- V1 of the predisposition data dictionary has been finalized.
- The C3P Steering Committee continues to meet monthly, and work to execute data contributor agreements continues.

Retinoblastoma (Global REACH)

- The Global REACH MOU is in final review stages prior to preparing for signature.
- Retinoblastoma data dictionary work continues to progress.

Soft Tissue Sarcoma (INSTRuCT)

- In December, INSTRuCT convened virtually for a Winter Meeting that included a plenary session with updates from all work groups as well as breakout sessions for a regional lymph nodes project and expanding/improving the data dictionary.

Thanks for reading!

We'll be back with another newsletter next quarter. In the meantime, [let us know your questions and feedback](#). We look forward to working together to transform pediatric cancer research!

—The UChicago PCDC Team